Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

Project: Research project

Project Details

StatusActive
Effective start/end date12/14/2311/30/28

Funding

  • HHS: National Institutes of Health (NIH): $3,950,448.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.